Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liliane Goetsch

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Biomarkers in Medicine|April 14, 2010
Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkersLiliane Goetsch, Véronique Caussanel
Immunotherapy|July 20, 2010
Insulin-like growth factor receptor type I as a target for cancer therapyLiliane Goetsch, Nathalie Corvaïa
Methods in Molecular Biology (Clifton, N.J.)|March 12, 2013
Evaluation of complement-dependent cytotoxicity using ATP measurement and C1q/C4b bindingLucile Broyer, Liliane Goetsch, Matthieu Broussas
Frontiers in Bioscience (Landmark Edition)|January 2, 2013
Biological significance and targeting of c-Met tyrosine kinase receptor in cancerLiliane Goetsch, Veronique Caussanel, Nathalie Corvaia
Methods in Molecular Biology (Clifton, N.J.)|March 12, 2013
Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurementMatthieu Broussas, Lucile Broyer, Liliane Goetsch
Frontiers in Bioscience (Scholar Edition)|January 2, 2013
Insulin-like growth factor receptor type I as a target for cancer therapyNathalie Corvaia, Alain Beck, Véronique Caussanel, et al.
Nature Reviews. Drug Discovery|March 18, 2017
Strategies and challenges for the next generation of antibody-drug conjugatesAlain Beck, Liliane Goetsch, Charles Dumontet, et al.
Biochemical Society Transactions|March 25, 2011
Tetraspanin CD151 as a target for antibody-based cancer immunotherapyJean-François Haeuw, Liliane Goetsch, Christian Bailly, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2007
Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptorsGiuseppe Pandini, Thierry Wurch, Barbara Akla, et al.
Discovery Medicine|November 2, 2010
The next generation of antibody-drug conjugates comes of ageAlain Beck, Jean-François Haeuw, Thierry Wurch, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Biomarkers in Medicine|April 14, 2010
Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkersLiliane Goetsch, Véronique Caussanel
Immunotherapy|July 20, 2010
Insulin-like growth factor receptor type I as a target for cancer therapyLiliane Goetsch, Nathalie Corvaïa
Methods in Molecular Biology (Clifton, N.J.)|March 12, 2013
Evaluation of complement-dependent cytotoxicity using ATP measurement and C1q/C4b bindingLucile Broyer, Liliane Goetsch, Matthieu Broussas
Frontiers in Bioscience (Landmark Edition)|January 2, 2013
Biological significance and targeting of c-Met tyrosine kinase receptor in cancerLiliane Goetsch, Veronique Caussanel, Nathalie Corvaia
Methods in Molecular Biology (Clifton, N.J.)|March 12, 2013
Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurementMatthieu Broussas, Lucile Broyer, Liliane Goetsch
Frontiers in Bioscience (Scholar Edition)|January 2, 2013
Insulin-like growth factor receptor type I as a target for cancer therapyNathalie Corvaia, Alain Beck, Véronique Caussanel, et al.
Nature Reviews. Drug Discovery|March 18, 2017
Strategies and challenges for the next generation of antibody-drug conjugatesAlain Beck, Liliane Goetsch, Charles Dumontet, et al.
Biochemical Society Transactions|March 25, 2011
Tetraspanin CD151 as a target for antibody-based cancer immunotherapyJean-François Haeuw, Liliane Goetsch, Christian Bailly, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2007
Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptorsGiuseppe Pandini, Thierry Wurch, Barbara Akla, et al.
Discovery Medicine|November 2, 2010
The next generation of antibody-drug conjugates comes of ageAlain Beck, Jean-François Haeuw, Thierry Wurch, et al.
Pageof 3